Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 1, 2005. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding share allocation arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of director share awards and does not contain financial performance data.
Material Changes
On July 1, 2005, non-executive directors were provisionally allocated awards of Ordinary Shares and American Depository Shares (ADSs) for the service period of April 1 to June 30, 2005. The specific allocations are as follows:
- Sir Christopher Gent: 1,858.74 Ordinary Shares
- Mr Lawrence Culp: 745.46 ADSs
- Sir Crispin Davis: 1,486.99 Ordinary Shares
- Sir Deryck Maughan: 745.46 ADSs
- Sir Ian Prosser: 1,022.30 Ordinary Shares
- Dr Ronaldo Schmitz: 669.14 ADSs
- Dr Lucy Shapiro: 186.36 ADSs
- Sir Robert Wilson: 464.68 ADSs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of director share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the final vesting status of the provisional share awards listed for non-executive directors.
- Confirm the total number of shares and ADSs outstanding following these allocations.
- Review the specific terms of the share allocation arrangements for the period of April 1 to June 30, 2005.